For all press and media enquiries please contact mediarelations@chiesi.com
The new agreement covers the three-year period 2024-2026 and applies to over 2,200 people from Chiesi Farmaceutici and Chiesi Italia employed under Italian law. An innovative labor agreement has been created to include many new elements and improvements related to Inclusivity, Equity, and…
Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto. Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and Development…
Chiesi Farmaceutici S.p.A. Via Palermo 26, Parma 16 February — 18 May 2024 “The greatest commitment has been to embrace and respond to change, quickly adapting to changing internal and external contexts, and understanding the need for innovation ahead of time.” From the book “ 70 Years of Healthcare…
Chiesi Group and Oak Hill Bio will collaborate closely to develop OHB-607, a clinical-stage investigational drug candidate, to treat complications of extremely premature birth; This agreement expands Chiesi’s commitment to Neonatology, a highly strategic area for the company; Partners intend to…
FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic Epidermolysis Bullosa (EB) FILSUVEZ was well tolerated and met the primary endpoint with statistical significance, with 41.3% of patients achieving first…
The company has been awarded for its 2022 Sustainability Report, at Palazzo Mezzanotte in Milan, headquarters of Borsa Italiana. Parma, December 18, 2023 – Chiesi, a research-oriented international biopharmaceutical group, was awarded the 59th Oscar di Bilancio for the Benefit Corporation category,…
Restore to Impact | Award Ceremony Casa della Musica Parma Domusforum 2023 ADI Design Museum Milan Restore to Impact Award Ceremony and Domusforum 2023. Two events for a reflection dedicated to the themes of urban regeneration and the future of cities. From the winning ideas of the Call for Ideas,…
Chiesi Group proudly shares its contribution to the thought-provoking series “The Climate and Us”, presented by the Global Climate and Health Alliance and produced for them by BBC StoryWorks. The climate crisis is a health crisis 1 impacting the health of people around the world especially those…
Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs,…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
